Glucotrack Merges With Lokahi Therapeutics; Former Holders to Own 90% Post-Conversion
I'm LongbridgeAI, I can summarize articles.Glucotrack merged with Lokahi Therapeutics, making Lokahi a subsidiary. Post-merger, Lokahi holders will own 90% of Glucotrack. To fund operations, Glucotrack raised ~$4.45 million via senior secured convertible notes and established a $50 million equity line with White Lion Capital. The company also granted security interests, obtained voting support, issued warrants, and signed registration rights agreements to ensure liquidity and listing compliance.
Glucotrack closed a stock-for-stock merger with Lokahi Therapeutics, making Lokahi a wholly owned subsidiary and setting Lokahi's former holders to own 90% of Glucotrack on an as-converted, fully diluted basis after preferred conversion, with a 10% floor for existing holders. To fund operations and post-closing steps, Glucotrack completed a ~$4.45 million senior secured convertible bridge financing and granted first-lien security, obtained voting support for required approvals, and established a three-year equity line of up to $50 million with White Lion. The company also issued a five-year commitment warrant and entered a registration rights agreement to facilitate resale of ELOC-related securities. Management expects these actions to support liquidity, listing compliance and strategic execution following the merger.
Agreement 1: Glucotrack Merges With Lokahi Therapeutics; Former Holders to Own 90% Post-Conversion
- Agreement type: Agreement and Plan of Merger
- Counterparty: Lokahi Therapeutics
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: One-time transaction
- Reason: Combine businesses and realign capital structure
Agreement 2: Glucotrack Raises ~$4.45 Million via Senior Secured Convertible Notes and Warrants
- Agreement type: Securities Purchase Agreement for senior secured convertible notes and warrants
- Counterparty: Bridge Investors
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: 9 months (notes)
- Reason: Bridge liquidity during post-merger transition
Agreement 3: Glucotrack Grants First-Lien Security to Back Bridge Notes
- Agreement type: Security Agreement securing bridge notes
- Counterparty: White Lion Capital
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: Until notes repaid
- Reason: Secure obligations under bridge financing
Agreement 4: Glucotrack Obtains Voting Support to Approve Bridge Issuances and Capital Actions
- Agreement type: Voting Support Agreement
- Counterparty: White Lion Capital and Supporting Stockholders
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: Until required approvals obtained
- Reason: Facilitate approvals for financing and listing compliance
Agreement 5: Glucotrack Secures Up to $50 Million Equity Line With White Lion
- Agreement type: Common Stock Purchase Agreement (Equity Line of Credit)
- Counterparty: White Lion Capital
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: 3 years
- Reason: Flexible access to equity capital
Agreement 6: Glucotrack Issues Five-Year Commitment Warrant as ELOC Consideration
- Agreement type: Commitment Warrant issuance
- Counterparty: White Lion Capital
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: 5 years
- Reason: Compensate ELOC provider and align incentives
Agreement 7: Glucotrack Grants Registration Rights for ELOC, Warrant and Related Shares
- Agreement type: Registration Rights Agreement
- Counterparty: White Lion Capital
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: Until resale registration obligations satisfied
- Reason: Enable resale liquidity for issued securities
Original SEC Filing: Glucotrack, Inc. [ GCTK ] - 8-K - Jul. 15, 2026